ArticleThe Journal of antimicrobial chemotherapy2012
Deferasirox as adjunctive therapy for mucormycosis.
Article in The Journal of antimicrobial chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Iron bioavailability regulates Pseudomonas aeruginosa interspecies interactions through type VI secretion expression.Cell reports · 2023Article
- Expression Patterns in Reductive Iron Assimilation and Functional Consequences during Phagocytosis ofJournal of fungi (Basel, Switzerland) · 2021Article
- Review
- Mucormycosis of the Central Nervous System.Journal of fungi (Basel, Switzerland) · 2019Review
- Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series.Infectious disease reports · 2018Article
- Immunomodulation as Therapy for Fungal Infection: Are We Closer?Frontiers in microbiology · 2018Review
- Iron starvation induces apoptosis in Rhizopus oryzae in vitro.Virulence · 2015Article
- Review
- Human Fungal Pathogens of Mucorales and Entomophthorales.Cold Spring Harbor perspectives in medicine · 2014Review
- Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Antimicrobial agents and chemotherapy · 2014Article
- Update on mucormycosis pathogenesis.Current opinion in infectious diseases · 2013Review
- Investigation of the biological properties of (hetero)aromatic thiosemicarbazones.Molecules (Basel, Switzerland) · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis can be devastating and, as yet, there are no ideal therapies available. Observations that iron chelation may be a useful adjunct to antifungal treatment encouraged Spellberg et al. (J Antimicrob Chemother 2012; 715-22) to undertake a trial of deferasirox combined with liposomal amphotericin B (AmBisome(®)) as short-term therapy for mucormycosis. The results were disappointing as patients treated with deferasirox had a higher mortality rate at 90 days, leading the authors to conclude that the data did not support a role for initial, adjunctive deferasirox therapy for mucormycosis. We review the issues arising from this study to help decide whether the evidence that now exists supports further studies or represents the end of this line of enquiry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.